MétaCan
Menu
← Back to cohort
Record W7117260917 · doi:10.1002/alz70858_098409

Treatment Patterns of Agitation associated with Alzheimer's Dementia (AAD) Patients in Canada

2025· article· en· W7117260917 on OpenAlexaffabout
Veronique Littmann, François Therrien, A. Marilise Marrache, Ceryl Tan, Natalie Nightingale, Calum S Neish, Zahinoor Ismail

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsHotchkiss Brain InstituteUniversity of CalgaryNanoQuébec (Canada)
Fundersnot available
KeywordsDementiaMEDLINEDiseaseClinical trialAlzheimer's disease

Abstract

fetched live from OpenAlex

Abstract Background Agitation associated with Alzheimer's dementia (AAD) is a challenging behavioral feature of Alzheimer's dementia (AD) characterized by excessive motor activity, verbal aggression, and physical aggression. Affecting up to 80% of people with AD, AAD is linked with greater caregiver burden, morbidity, and mortality. Due to a paucity of approved AAD treatments, therapeutic strategies may vary across clinicians. To gain insights into clinical practice, we examined the treatment patterns of AAD patients in Canada. Method This was a retrospective cohort study using public drug plan claims data from Ontario and New Brunswick between 2003 and 2023 to characterize lines of therapy (LoTs). An indication algorithm was developed with a clinical expert to identify AAD through prescription claims for cognitive enhancers and medications commonly used to treat AAD symptoms (anticonvulsants [AC], antidepressants [ADT], antipsychotics [AP], benzodiazepines [benzo]). These inferred patients were indexed on the date of their first AC/ADT/AP/benzo and analyzed until their 4 th LoT. Result Overall, 23,732 inferred AAD patients were identified, mostly from Ontario, with a median (IQR) age of 80 (11) years (Table 1). Overall, 70% of the cohort were followed until the end of their 4 th LoT (4L), and the proportion of those in a long‐term care setting increased from 14% (1L) to 54% (4L) (Figure 1). Inferred AAD patients were treated with a wide range of therapies, with over 500 to 2000 unique combinations observed across 1L to 4L, respectively. However, some medications and their combinations consistently ranked among the top ten most common therapies across LoT: citalopram, escitalopram, gabapentin, lorazepam, mirtazapine, pregabalin, quetiapine, risperidone, sertraline, and trazodone (Figure 2). The top ten therapies accounted for 73% of all 1L treatment approaches, with only risperidone indicated at that time for managing aggression and psychotic symptoms in severe AD. The highest proportion of patients remained on their 3L‐4L therapy after one year; the majority (≥80%) were adherent to these medications across all LoTs. Conclusion There is considerable variability in AAD‐related treatment approaches among Canadian clinicians. Our findings highlight the need for more evidence on treatments specifically indicated for AAD, and education to facilitate evidence‐based clinical practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.024
Threshold uncertainty score0.171

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0020.005
Science and technology studies0.0020.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.279
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicDementia and Cognitive Impairment Research→French-language works237,207→